Movatterモバイル変換


[0]ホーム

URL:


EA201400966A1 - REMIELINIZATION OF PERIPHERAL NERVES, Stimulated by IgG - Google Patents

REMIELINIZATION OF PERIPHERAL NERVES, Stimulated by IgG

Info

Publication number
EA201400966A1
EA201400966A1EA201400966AEA201400966AEA201400966A1EA 201400966 A1EA201400966 A1EA 201400966A1EA 201400966 AEA201400966 AEA 201400966AEA 201400966 AEA201400966 AEA 201400966AEA 201400966 A1EA201400966 A1EA 201400966A1
Authority
EA
Eurasian Patent Office
Prior art keywords
peripheral
polyclonal igg
igg
myelin
differentiation
Prior art date
Application number
EA201400966A
Other languages
Russian (ru)
Other versions
EA032000B1 (en
Inventor
Патрик Кюри
Невена Цекова
Ханс-Петер Хартунг
Коринна Херманн
Биргит Мария Райперт
Ханс-Петер Шварц
Хартмут Эрлих
Зебастьян Бунк
Original Assignee
Бакстер Интернэшнл Инк.
Бакстер Хелткэр С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бакстер Интернэшнл Инк., Бакстер Хелткэр С.А.filedCriticalБакстер Интернэшнл Инк.
Publication of EA201400966A1publicationCriticalpatent/EA201400966A1/en
Publication of EA032000B1publicationCriticalpatent/EA032000B1/en

Links

Classifications

Landscapes

Abstract

Translated fromRussian

Настоящее изобретение основано на открытии способности поликлональных IgG стимулировать созревание, дифференциацию шванновских клеток и выработку ими миелина. Представлены способы лечения неидиопатических демиелинизирующих периферических нейропатий у млекопитающих, при этом нейропатия не является иммуноопосредованной или инфекционно-опосредованной, путем введения поликлональных IgG. Типы демиелинизирующих периферических нейропатий, подлежащие лечению при помощи настоящего изобретения, включают травму периферического нерва и периферическую нейропатию, вызванную воздействием токсинов. В качестве альтернативы, композицию поликлональных IgG можно наносить непосредственно на периферическую нервную клетку, чтобы стимулировать созревание, дифференциацию в миелинизирующее состояние, экспрессию миелина или способствовать выживанию клеток.The present invention is based on the discovery of the ability of polyclonal IgG to stimulate the maturation, differentiation of Schwann cells and their production of myelin. Presents methods for the treatment of non-idiopathic demyelinating peripheral neuropathies in mammals, while neuropathy is not immune-mediated or infectious-mediated, by introducing polyclonal IgG. Types of demyelinating peripheral neuropathies to be treated with the present invention include peripheral nerve injury and peripheral neuropathy caused by exposure to toxins. Alternatively, a polyclonal IgG composition can be applied directly to a peripheral nerve cell to stimulate maturation, differentiation into a myelinating state, expression of myelin, or promote cell survival.

EA201400966A2012-02-292013-02-28 METHODS OF TREATMENT OF DEMIELINIZING PERIPHERAL NEUROPATHY CAUSED BY INJURYEA032000B1 (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US201261605117P2012-02-292012-02-29
PCT/US2013/028350WO2013130826A2 (en)2012-02-292013-02-28Igg stimulated remyelination of peripheral nerves

Publications (2)

Publication NumberPublication Date
EA201400966A1true EA201400966A1 (en)2014-12-30
EA032000B1 EA032000B1 (en)2019-03-29

Family

ID=47884569

Family Applications (2)

Application NumberTitlePriority DateFiling Date
EA201892521AEA201892521A1 (en)2012-02-292013-02-28 REMYELINIZATION OF PERIPHERAL NERVES, STIMULATED IgG
EA201400966AEA032000B1 (en)2012-02-292013-02-28 METHODS OF TREATMENT OF DEMIELINIZING PERIPHERAL NEUROPATHY CAUSED BY INJURY

Family Applications Before (1)

Application NumberTitlePriority DateFiling Date
EA201892521AEA201892521A1 (en)2012-02-292013-02-28 REMYELINIZATION OF PERIPHERAL NERVES, STIMULATED IgG

Country Status (21)

CountryLink
US (5)US8986670B2 (en)
EP (2)EP3590960B1 (en)
JP (3)JP6335800B2 (en)
KR (3)KR20200126005A (en)
CN (4)CN104302666A (en)
AR (2)AR090211A1 (en)
AU (3)AU2013203088B2 (en)
BR (1)BR112014021240A2 (en)
DK (2)DK2820042T3 (en)
EA (2)EA201892521A1 (en)
ES (2)ES2943585T3 (en)
FI (1)FI3590960T3 (en)
HK (1)HK1248534A1 (en)
IL (3)IL274512B2 (en)
MX (2)MX369444B (en)
NZ (1)NZ629867A (en)
PL (2)PL2820042T3 (en)
PT (2)PT2820042T (en)
SG (1)SG11201405302WA (en)
TW (3)TWI700297B (en)
WO (1)WO2013130826A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN104302666A (en)*2012-02-292015-01-21巴克斯特国际公司 IgG of peripheral nerves stimulates remyelination
US9690975B2 (en)*2015-05-282017-06-27Axogen CorporationQuantitative structural assay of a nerve graft
WO2019099902A1 (en)2017-11-172019-05-23The Research Foundation for State University of New YorkA method for treating damaged peripheral nerves using x-ray microbeam irradiation
WO2020146370A1 (en)*2019-01-072020-07-16Mallinckrodt Ard Ip LimitedMethods of promoting remyelination
WO2025005230A1 (en)*2023-06-302025-01-02富士フイルム株式会社Method for evaluating intercellular interaction of neuroinflammation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
SE348942B (en)1970-06-021972-09-18Statens Bakteriologiska Labor
DK166763C (en)1983-03-161993-07-12Immuno Ag IMMUNOGLOBULIN-G-CONTAINING FRACTION
AT376367B (en)1983-03-161984-11-12Immuno Ag METHOD FOR PRODUCING THERAPEUTICALLY AVAILABLE PLASMA DERIVATIVES FILLED IN TERMINAL CONTAINERS
EP0124506B1 (en)1983-05-021988-08-17IMMUNO Aktiengesellschaft für chemisch-medizinische ProdukteMethod of inactivating pathogens
AT389815B (en)1984-03-091990-02-12Immuno Ag METHOD FOR INACTIVATING VARIABLE FILTERABLE DISEASERS IN BLOOD PRODUCTS
AT390560B (en)1986-05-301990-05-25Immuno Ag METHOD FOR INACTIVATING VARIABLE FILTERABLE DISEASES
JP2871709B2 (en)1988-11-211999-03-17住友製薬株式会社 Novel protein H having immunoglobulin G binding activity, gene encoding the protein, and method for producing the protein
US5177194A (en)1990-02-011993-01-05Baxter International, Inc.Process for purifying immune serum globulins
AU8649391A (en)*1990-08-151992-03-17University Of MiamiAutotransplantation of schwann cells to promote nervous system repair
AT402891B (en)1991-06-201997-09-25Immuno Ag METHOD FOR PRODUCING AN INACTIVATED BLOOD PRODUCT
EP0674531A1 (en)1992-12-161995-10-04IMMUNO AktiengesellschaftProcess for preparing a virus-safe biological composition
FR2706466B1 (en)1993-06-141995-08-25Aetsrn Immunoglobulin G concentrate for therapeutic use and process for producing said concentrate.
HRP940645A2 (en)1993-10-061996-12-31Immuno AgProcess for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
TW491855B (en)1996-08-072002-06-21Csl LtdPurification of immunoglobulins
US5886154A (en)1997-06-201999-03-23Lebing; Wytold R.Chromatographic method for high yield purification and viral inactivation of antibodies
ES2229784T3 (en)1998-06-092005-04-16Statens Serum Institut IMMUNOGLOBULIN PRODUCTION PROCESS FOR INTRAVENOUS ADMINISTRATION AND OTHER IMMUNOGLOBULIN PRODUCTS.
SE0001128D0 (en)2000-03-302000-03-30Amersham Pharm Biotech Ab A method of producing IgG
AU6197800A (en)*2000-05-102001-11-20Mayo FoundationHuman igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
FR2824568B1 (en)2001-05-112004-04-09Lab Francais Du Fractionnement PROCESS FOR THE PREPARATION OF HUMAN IMMUNOGLOBULIN CONCENTRATES FOR THERAPEUTIC USE
JP2003070465A (en)*2001-08-312003-03-11Keio Gijuku Schwann cell culture method
KR101260497B1 (en)2003-01-242013-09-12엘란 파마슈티칼스, 인크.Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
WO2005073252A1 (en)2004-01-302005-08-11Suomen Punainen Risti VeripalveluProcess for the manufacture of virus safe immunoglobulin
BRPI0508096B8 (en)2004-02-272021-05-25Octapharma Ag method of preparing a safe purified antibody preparation against virus and inactivated virus
GEP20135853B (en)*2007-02-022013-06-25Univ Pierre And Marie CurieMethod of myelination and oligodendrocyte differentiation promotion
US7854703B2 (en)2007-09-252010-12-21Intel CorporationPeripheral neuropathy detection
CA2643496C (en)2008-11-062015-02-03Michael FehlingsThe therapeutic use of igg as a neuroprotective agent
CN102021140B (en)*2009-09-182013-04-24上海市第一人民医院Method for separating and purifying schwann cells
CN104302666A (en)*2012-02-292015-01-21巴克斯特国际公司 IgG of peripheral nerves stimulates remyelination

Also Published As

Publication numberPublication date
TW201838654A (en)2018-11-01
TWI700297B (en)2020-08-01
CN110343171A (en)2019-10-18
EP2820042A2 (en)2015-01-07
DK2820042T3 (en)2019-10-28
JP6637934B2 (en)2020-01-29
US8986670B2 (en)2015-03-24
US20130224150A1 (en)2013-08-29
US20200216518A1 (en)2020-07-09
JP2015508824A (en)2015-03-23
EA032000B1 (en)2019-03-29
US20210300997A1 (en)2021-09-30
WO2013130826A3 (en)2013-12-05
ES2943585T3 (en)2023-06-14
IL277103A (en)2020-10-29
CN107551269A (en)2018-01-09
IL274512A (en)2020-06-30
AU2016201137A1 (en)2016-03-10
CN109966488A (en)2019-07-05
AR090211A1 (en)2014-10-29
EP2820042B1 (en)2019-07-24
IL274512B2 (en)2024-07-01
PT3590960T (en)2023-04-18
IL234303B (en)2020-09-30
NZ629867A (en)2016-09-30
PL3590960T3 (en)2023-07-17
EP3590960A1 (en)2020-01-08
IL274512B1 (en)2024-03-01
DK3590960T3 (en)2023-04-24
AR117207A2 (en)2021-07-21
JP2018030856A (en)2018-03-01
KR20220045087A (en)2022-04-12
US20180291087A1 (en)2018-10-11
HK1248534A1 (en)2018-10-19
TW201736398A (en)2017-10-16
AU2018200026B2 (en)2019-12-05
AU2016201137B2 (en)2017-10-12
US10494418B2 (en)2019-12-03
CN104302666A (en)2015-01-21
SG11201405302WA (en)2014-09-26
JP6979990B2 (en)2021-12-15
KR20200126005A (en)2020-11-05
TW201400502A (en)2014-01-01
HK1206035A1 (en)2015-12-31
MX2019012496A (en)2020-01-20
ES2755056T3 (en)2020-04-21
KR20140134690A (en)2014-11-24
US20150232536A1 (en)2015-08-20
JP6335800B2 (en)2018-05-30
EP3590960B1 (en)2023-03-29
JP2020059705A (en)2020-04-16
BR112014021240A2 (en)2018-09-18
KR102170615B1 (en)2020-10-28
IL277103B2 (en)2025-07-01
MX369444B (en)2019-11-08
EA201892521A1 (en)2019-07-31
AU2013203088A1 (en)2013-09-19
MX2014010387A (en)2015-09-25
AU2013203088B2 (en)2015-12-03
IL277103B1 (en)2025-03-01
PL2820042T3 (en)2020-03-31
AU2018200026A1 (en)2018-01-25
US9834593B2 (en)2017-12-05
FI3590960T3 (en)2023-04-25
PT2820042T (en)2019-10-31
TWI632158B (en)2018-08-11
KR102673154B1 (en)2024-06-05
WO2013130826A2 (en)2013-09-06

Similar Documents

PublicationPublication DateTitle
UA107812C2 (en) DUAL-SUBSTITUTED OCTAHYDROPYROLO $ 3.4-c] PYROLS AS MODULATORS OF OREXIN RECEPTORS
MX2022004300A (en)Composition and method for diagnosis and treatment of diseases associated with neurite degeneration.
IN2015DN00438A (en)
EA201400966A1 (en) REMIELINIZATION OF PERIPHERAL NERVES, Stimulated by IgG
MY200941A (en)(r)- and (s)-1-(3-(3-n,n-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-n,n-bis(ethylene)phosphoramidate, compositions and methods for their use and preparation
PH12014502449A1 (en)Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
SG10201914117QA (en)Treatment Of Myelosuppression
PH12014500767A1 (en)Compositions for the treatment of dry eye
EA201590870A1 (en) AMINO-SUBSTITUTED IMIDAZO [1,2-a] Pyridinecarboxamides and their use
CL2010001159A1 (en) Compounds derived from 3,8-diazabicyclo [2.4.0] octane and 3,6-diazabicyclo [3.2.0] heptane disubstituted, orexin receptor modulators; pharmaceutical composition; Useful in the treatment of sleep disorders, metabolic disorders, among others.
EA201890020A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF ASSOCIATED WITH AGING STATES
MX2013006056A (en)Methods for diagnosing and treating eye-length related disorders.
EA201792437A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH AGING
EA201290744A1 (en) IMIDAZO [1,2-B] [1,2,4] TRIAZINS AS C-MET INHIBITORS
EA201390826A1 (en) PYRIMIDINOUS CONNECTIONS FOR USE IN TREATING DISEASES OR STATES MEDIATED BY Lp-PLA
HK1211085A1 (en) Method for treating iron deficiency anemia
EA201492102A1 (en) ANTAGONISTS LINGO-2 FOR THE TREATMENT OF DISEASES IN WHICH MOTOR NEURONS PARTICIPATE
EA033335B1 (en)Il-21 antibody and use thereof for the treatment of an autoimmune condition
MX356933B (en)Composition and method for the diagnosis and treatment of iron-related disorders.
CA3010708A1 (en)Methods of administering hepcidin
EA201170447A1 (en) IZOHINOLINON DERIVATIVES AS ANTAGONISTS NK3
SG10201811203TA (en)Protocols for treatment of major depressive disorder (mdd)
AU2016204146A1 (en)Methods of Increasing Neuronal Differentiation Using Antibodies to Lysophoshatidic Acid
WO2013106766A3 (en)THERAPEUTIC INDICATIONS OF miR-1291
WO2015040497A3 (en)Methods for nuclear reprogramming of cells

Legal Events

DateCodeTitleDescription
MM4ALapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s):AZ KG TJ TM

PC4ARegistration of transfer of a eurasian patent by assignment
MM4ALapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s):AM


[8]ページ先頭

©2009-2025 Movatter.jp